SEC Company Response from Histogen Inc. (CIK 0001383701) — Mar 30, 2020
Histogen Inc. (CIK 0001383701)
Date: March 30, 2020 · CIK: 0001383701 · Accession: 0001193125-20-091070
AI Filing Summary & Sentiment
File numbers found in text: 333-236332
Letter
VIA EDGAR Division of Corporation Finance Securities and Exchange Commission Re: Conatus Pharmaceuticals Inc. Registration Statement on Form S-4 Filed February 7, 2020 (as amended March 13, 2020) File No. 333-236332
Dear Mr. Fischer:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Conatus Pharmaceuticals Inc., respectfully requests that the effective date of the Registration Statement on Form S-4 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on April 1, 2020, or as soon as practicable thereafter.
If you have any questions or require additional information, please contact Matthew T. Bush, Esq. of Latham & Watkins LLP at (858) 523-3962. Thank you for your assistance and cooperation in this matter.
Very truly yours,
CONATUS PHARMACEUTICALS INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Conatus Pharmaceuticals Inc. 16745 West Bernardo Drive, Suite 250 San Diego, CA 92127 March 30, 2020 VIA EDGAR Paul Fischer Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Conatus Pharmaceuticals Inc. Registration Statement on Form S-4 Filed February 7, 2020 (as amended March 13, 2020) File No. 333-236332 Dear Mr. Fischer: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Conatus Pharmaceuticals Inc., respectfully requests that the effective date of the Registration Statement on Form S-4 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on April 1, 2020, or as soon as practicable thereafter. If you have any questions or require additional information, please contact Matthew T. Bush, Esq. of Latham & Watkins LLP at (858) 523-3962. Thank you for your assistance and cooperation in this matter. Very truly yours, CONATUS PHARMACEUTICALS INC. By: /s/ Steven J. Mento, Ph.D. Steven J. Mento, Ph.D. Chief Executive Officer cc: Matthew T. Bush, Esq., Latham & Watkins LLP Anthony A. Gostanian, Esq., Latham & Watkins LLP